HAEMATO AG (HAM:HAEK)

Market Cap	52.28M -12.7%
Revenue (ttm)	260.81M +2.5%
Net Income	9.61M +2,578.0%
EPS	1.88 +2,605.8%
Shares Out	5.23M
PE Ratio	5.33
Forward PE	n/a
Dividend	0.04 (0.40%)
Ex-Dividend Date	Jul 16, 2025

Volume	758
Average Volume	972
Open	10.00
Previous Close	10.00
Day's Range	10.00 - 10.00
52-Week Range	8.20 - 14.10
Beta	0.19
RSI	56.43
Earnings Date	n/a

About HAEMATO AG

HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, special cosmetics, as well as dietary supplements. In addition, it provides pharmaceuticals in the areas of HIV/AIDS, neurology, oncology, and rheumatology diseases. Further, the company develops, manufactures, and distributes diagnostic tests under the HAEMATO...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 1993
• Employees: 76
• Stock Exchange: Hamburg Stock Exchange
• Ticker Symbol: HAEK

Financial Performance

In 2022, HAEMATO AG's revenue was 248.14 million, a decrease of -12.95% compared to the previous year's 285.04 million. Earnings were 8.19 million, an increase of 25.39%.